Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "SARS-COV-2"


25 mentions found


[1/2] The World Health Organization logo is pictured at the entrance of the WHO building, in Geneva, Switzerland, December 20, 2021. REUTERS/Denis BalibouseLONDON, Jan 3 (Reuters) - Leading scientists advising the World Health Organization said they wanted a "more realistic picture" about the COVID-19 situation from China's top experts at a key meeting on Tuesday as worries grow about the rapid spread of the virus. The WHO has invited Chinese scientists to a virtual closed meeting with its technical advisory group on viral evolution on Tuesday, to present data on which variants are circulating in the country. Speaking to Reuters ahead of the meeting, she said some of the data from China, such as hospitalisation numbers, is "not very credible". A WHO spokesperson said that a "detailed discussion" was expected about circulating variants in China, and globally, with Chinese scientists expected to make a presentation.
Rapid tests have always been second to polymerase chain reaction, or PCR, assays when it comes to accuracy. Home-test kits have expiration datesAt-home COVID-19 test kits are one of the more convenient inventions to come out of the pandemic. Over-the-counter test kits typically have a sticker on the box indicating an expiration date and manufacturing date. One study found that false positives showed up when unexpected substances were directly applied to test kits. That is if you use the rapid test correctly and wait at least three-to-five days since a COVID-19 exposure to swab yourself.
CHICAGO, Dec 28 (Reuters) - The United States will impose mandatory COVID-19 tests on travelers from China, U.S. health officials said on Wednesday, joining India, Italy, Japan and Taiwan in taking new measures after Beijing's decision to lift stringent zero-COVID policies. The United States also is expanding its voluntary genomic sequencing program at airports, adding Seattle and Los Angeles to the program. Beijing has faced international criticism that its official COVID data and its tally of deaths are inconsistent with the scale of its outbreak. In June, the United States rescinded a 17-month-old requirement that people arriving in the country by air test negative for COVID-19. It still requires most non-U.S. citizens to be vaccinated against COVID to travel to the United States.
The country will also scrap all other restrictive Covid measures for travelers, including quarantines for positive patients and contact tracing. China downgraded Covid management to a less-strict “Class B disease,” in the same category as less-severe diseases, such as Dengue fever. The existing quarantine policy for international arrivals to China was first launched in 2020 and modified over the course of the past several years. Since the world’s second largest economy drastically eased its Covid restrictions, there has been no clear data on the extent of the virus’ spread on the national level. China’s current focus is to prepare sufficient medical resources, according to the NHC statement.
China’s Let-It-Rip Covid Reopening
  + stars: | 2022-12-23 | by ( Ezekiel J. Emanuel | ) www.wsj.com   time to read: 1 min
China put the world in peril with its coverup and slow response to the emergence of SARS-CoV-2 three years ago. The country’s current approach to Covid-19 is creating new risks—in China and beyond. Xi Jinping has made an abrupt about-face—swinging from total Covid suppression to population-wide immunity through viral spread. Chinese experts predict a Covid explosion, with hundreds of millions of cases. China will also become a petri dish for new variants, which will inevitably spread globally.
The Philadelphia school district announced Wednesday that students and staff will be required to wear masks indoors for two weeks in January in an effort to slow transmission after the holidays. The New York City Department of Education issued a letter this week strongly encouraging students and staff to wear a well-fitting mask indoors. After three years of Covid, however, experts recognized that few people are inclined to wear masks as often as they had previously while in public spaces. But Luby said he still wears a mask in public, even when others around him do not. “I find myself in that situation a lot — I’m the only person in the room wearing a mask," he said.
That's according to two studies that were published in August and November of this year, which researched how exposure to younger kids and common colds may impact outcomes for adults after contracting Covid-19. Exposure to kids may lower your risk of hospitalization from Covid-19The study, published in Proceedings of the National Academy of Sciences (PNAS) in August, discovered an association between people who were exposed to young children and lower risk of severe illness from Covid-19. And researchers compared the severity of outcomes from Covid-19 for people without children and people with children in three different age ranges: 0-5, 6-11 and 12-18. The findings showed that chances of Veteran Affairs patients contracting Covid-19 decreased by 80% to 90% if they tested positive for any of the common coronaviruses between February 2020 and February 2021. This means developing a common cold may shield people from Covid-19 infection, even if for a short period time.
Research published Monday has confirmed a link between a Covid infection and a debilitating heart condition called POTS, or postural orthostatic tachycardia syndrome, that has been diagnosed in some patients with long Covid. POTS was also linked, to a lesser degree, to Covid vaccination with an mRNA vaccine, according to the new study. He also said that the link between POTS and Covid vaccination needs to be confirmed with further studies. Other vaccines have also been linked to POTS in early accounts, but further research did not establish a causal link. The link between an infection — including Covid — and POTS, however, is more well-established.
Pepto-Bismol, the familiar pink over-the-counter medicine, might be expected to ease diarrhea symptoms in people with or without COVID-19. The claim that “big pharma” is hiding the benefits of Pepto-Bismol as a treatment for COVID-19 is part of a narrative that COVID-19 was manufactured for the pharmaceutical industry as a source of profit, previously debunked by Reuters (here). Bruce Yacyshyn, an adjunct professor at the University of Cincinnati and co-principal investigator of the Pepto-Bismol clinical trial, told Reuters via email that there was a valid scientific reason to test the medication in the context of COVID-19. But it remained as yet an “unproven treatment” for the virus because “no placebo controlled, randomized clinical trial data is yet available for this drug in this indication.”WHY PEPTO-BISMOL? There is no scientific evidence that Pepto-Bismol provides any benefit as a treatment for COVID-19, and a clinical trial testing that question has not yet produced results.
Dec 2 (Reuters) - Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a rise in infections, the head of the World Health Organization said on Friday. BAY ISMOYO/Pool via REUTERS 1 2"Gaps in testing ... and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality," Tedros said. COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline. Further easing of COVID-19 testing requirements and quarantine rules in some Chinese cities was met with a mix of relief and worry on Friday, as hundreds of millions await an expected shift in national virus policies after widespread social unrest. The WHO urged governments globally to focus on reaching those at risk, such as people over the age of 60 and those with underlying conditions, for vaccination.
Polymerase chain reaction (PCR) test kits for COVID-19 use what’s known as gene cloning – not reproductive cloning – to detect the presence or absence of the SARS-CoV-2 virus, but social media posts claim that humans are being cloned using COVID-19 PCR tests. The claim appears to originate from an Aug. 18 segment of the Stew Peters Show titled, “Patent PCR Test Linked To Human Cloning Video Shows Animal Experiments, Cross Species Genetics” (here). The 2015 paper by Hoseini and Sauer explains methods for gene cloning with PCR and used a gene encoding a red fluorescent protein as its example. PCR tests for COVID-19 cannot be used for human cloning. Molecular cloning, or gene cloning, that is described in a 2015 paper about using PCR to copy individual genes is an entirely different process.
CNN —The Covid-19 pandemic has carried a key lesson for public health officials, Dr. Anthony Fauci said Monday: When talking to Americans, be clear that science is often a moving target. “Hopefully, we could have been more on top of appreciating the dynamic nature of how things change, thinking that it wasn’t aerosol spread in the beginning, and then you find out it is aerosol spread. Experts agree that the virus almost certainly jumped into humans from an animal market in China but that they may never know for sure. “It’s possible that there was a lab leak,” Fauci said. Fauci criticized China’s controversial zero-Covid policy, saying shutdowns “should always be a temporary phenomenon, not a long-range strategy,” and should be done with an end point in mind, such as buying time to secure PPE or provide vaccinations.
A new pact is a priority for WHO chief Tedros Adhanom Ghebreyesus as his second five-year term at the head of the global health agency gets underway. It seeks to shore up the world's defences against new pathogens following the COVID-19 pandemic that has killed more than 6.5 million people, according to the WHO. The global health agency itself is facing calls for reform after an independent panel described it as "underpowered" when COVID-19 struck, with limited ability to investigate outbreaks and coordinate containment measures. The WHO already has binding rules known as the International Health Regulations (2005) which set out countries' obligations where public health events have the potential to cross borders. Adopted after the 2002/3 SARS outbreak, these regulations are still seen as functional for regional epidemics like Ebola but inadequate for a global pandemic.
Moderna’s updated Covid booster appears to increase the immune response to omicron subvariants BA.4 and BA.5, as well as another subvariant, called BQ.1.1, that's gaining ground in the United States, the company said in a release Monday. The results are based on blood samples taken from 511 adults who got the updated booster, which targets BA.4 and BA.5, along with the original coronavirus strain, in a single shot. In people who got the updated booster, neutralizing antibodies against BA.4 and BA.5 were about fivefold higher in those with a previous Covid infection and sixfold higher in those without a documented infection, the company said. Moderna also said an ​​additional analysis of 40 people found the updated booster demonstrated “robust neutralizing activity” against the subvariant BQ.1.1, though the response wasn’t as strong as what was seen against BA.4 and BA.5. Earlier this month, Pfizer and BioNTech said their updated booster shot generated a stronger immune response against BA.4 and BA.5 compared with their original Covid vaccine.
Social media users in Singapore are copy-pasting a text post which warns that the COVID-19 Omicron XBB variant, first discovered in August, is five times more “toxic” and has a higher mortality rate than the Delta variant. However, there is no evidence to support this, according to Singapore’s Ministry of Health. Likewise, the World Health Organisation (WHO) says current data does not suggest XBB is more deadly than Omicron, which itself is less lethal than Delta. There is, however, early evidence pointing at a higher reinfection risk, as compared to other circulating Omicron sublineages.”VERDICTFalse. There is no evidence the SARS-CoV-2 Omicron XBB variant is more deadly or causes more severe COVID-19 than the Delta variant.
"Reinfection with COVID-19 increases the risk of both acute outcomes and long COVID," said Dr. Ziyad Al-Aly of Washington University School of Medicine in St. Louis. "Even if one had prior infection and was vaccinated - meaning they had double immunity from prior infection plus vaccines - they are still susceptible to adverse outcomes upon reinfection," Al-Aly, the study leader, said. The higher risks were most pronounced in the first month after reinfection but were still evident six months later. The cumulative risks and burdens of repeat infection increased with the number of infections, even after accounting for differences in COVID-19 variants such as Delta, Omicron and BA.5, the researchers said. "We had started seeing a lot of patients coming to the clinic with an air of invincibility," Al-Aly told Reuters.
The recently authorized booster vaccine protects against the original SARS-CoV-2 virus and the more recent omicron variants, BA.4 and BA.5. But there's a new batch of so-called "Scrabble" variants circulating globally. But experts still expect the shots to ramp up your immunity against all Covid variants, to some degree. The Scrabble variants are descendants of omicronThe new variants are descendants of omicron, which is a promising initial sign for the boosters. That can "restore a level of immunity and patch up the holes that some of these new Scrabble variants have found," she explains.
Across the United States, cases of respiratory syncytial virus, or RSV, and influenza are increasing. Influenza activity continues to increase in the US – the number of flu illnesses, hospitalizations and deaths so far this season nearly doubled in the past week. RSV cases are also increasing nationally, although there are regional differences in the circulation of these viruses, Romero said. In the South and Mountain West, RSV cases appear to have peaked in October. There are signs that RSV cases are slowing in the southern region of the US, but test positivity rates and cases continue to rise in other regions, especially the Midwest.
The following describes the new coronavirus subvariants and how they may impact people. WHAT ARE BQ.1 AND BQ.1.1? In early July, BA.5 became the dominant subvariant of the coronavirus circulating in the United States, but in October it started giving way to BQ.1 and BQ.1.1. A study of blood from three dozen adults showed the shot increased neutralizing antibodies against the BA.4/BA.5 Omicron subvariants by fourfold compared with the original shot after one month. read moreIt is not yet clear whether that will translate into higher protection against the BQ.1 and BQ.1.1 subvariants, but their close relationship to BA.5 may work in the booster's favor.
CNN —The Omicron BA.5 subvariant is no longer the dominant cause of Covid-19 infections in the United States, according to estimates released Friday by the US Centers for Disease Control and Prevention. The gaggle of new variants have been gaining ground against BA.5, which has dominated Covid-19 infections in the United States since July. Together, they now account for more than 1 in 4 new Covid-19 infections nationwide, according to CDC data. BQ.1.1 is now causing about 1 in 5 new Covid-19 infections in the Northeast, where cases and hospitalizations are rising. But that strain is causing just 3% of new Covid-19 infections in the Pacific Northwest.
The recently authorized booster vaccine protects against the original SARS-CoV-2 virus and the more recent omicron variants, BA.4 and BA.5. The Food and Drug Administration said two studies this week showing that the new omicron boosters weren't that much better than the old shots were too small to come to any real conclusions. The antibody responses were slightly higher with the omicron boosters, though the studies concluded the difference wasn't significant. The studies are of public interest because there's very limited human data on how the omicron BA.5 boosters perform right now. The FDA also looked at data directly on the BA.5 shots that came from animal studies.
The authors then infected different sets of transgenic mice designed to be susceptible to SARS-CoV-2 with one of the three strains: Omicron, the ancestral virus, or the Omi-S hybrid virus (here). In the study, 100% of mice infected with the ancestral virus strain died, while 80% of those infected with Omi-S died, and none of the mice infected with Omicron died. Others shared the claim that the Omi-S had an “80% kill rate,” without specifying whether this referred to mice or humans. The ancestral virus (the viruses as they were when introduced in Europe and the US) in this mouse model kills 100% of the animals. Early in the pandemic, the fatality rate of the ancestral virus for people in a multicountry European analysis was estimated at about 4% (here).
To get emergency approval, companies needed to show that the vaccines were safe and prevented vaccinated people from getting ill. They did not have to show that the vaccine would also prevent people from spreading the virus to others. Pfizer ‘vaccine’ wasn’t intended to prevent transmission. The newest family of Omicron variants has further eroded vaccine effectiveness against infection and transmission (here) . But even Omicron does not escape vaccine protection completely.
REUTERS/Carlo AllegriOct 13 (Reuters) - Most patients with COVID-19 who have lingering symptoms at 12 months are likely to still have symptoms at 18 months, new data suggest. Among a subset of 197 survivors of symptomatic SARS-CoV-2 infections who completed surveys at 12 months and 18 months, most reported lingering symptoms at both time points, researchers reported in Nature Communications. Register now for FREE unlimited access to Reuters.com RegisterRates of no recovery at 12 months were 11% with 51% partial recovery and 39% complete recovery. At six months, 8% reported no recovery, 47% reported partial recovery, and 45% reported complete recovery. Those rates had barely changed at 12 months, with 8% reporting no recovery, 46% partial recovery and 46% complete recovery.
Not so China itself - in cities big or small, routine PCR testing is the new normal. read moreRegister now for FREE unlimited access to Reuters.com RegisterTens of thousands of kerbside sampling booths where people can be tested day and night have become a permanent feature of Chinese cityscapes. Testing booths, typically container-like structures erected in the middle of a pavement, are staffed by a few health workers in hazmat suits ready to take quick throat swabs. "Doing a PCR test every two days, I really feel it's a pure waste of resources," posted one user of Weibo, a popular Twitter-like microblog in China. Register now for FREE unlimited access to Reuters.com RegisterReporting by Ryan Woo; Editing by Kenneth MaxwellOur Standards: The Thomson Reuters Trust Principles.
Total: 25